Book Value per Share: SELLAS Life Sciences Group, Inc. (SLS)

Graphic logo of SELLAS Life Sciences Group Inc. (SLS)

This chart shows the market price of SELLAS Life Sciences (SLS) on the GURU.Markets platform at 0.68. The company's operations are protected by global humanitarian law and remain independent of sanctions. The business focuses on the commercialization of myeloid leukemia therapy through successful clinical trials. The uniqueness of the approach lies in GPS technology, which trains the immune system to recognize the WT1 protein to combat relapses.

SLS (SELLAS Life Sciences) Book Value per Share history from 07/04/2022 to 10/27/2026

Summary analytical data breakdowns for SELLAS Life Sciences Group, Inc. (SLS)

- price and consensus price forecast:
Price Chart SELLAS Life Sciences Group Inc.|SLS - Analyst Median Target
- market capitalization data:
Market Capitalization SELLAS Life Sciences Group|SLS - Real Price to Acquire Entire Company
- book capitalization data:
Book Value per Share SELLAS Life Sciences|SLS - Book Capitalization|Market Value to Book Value Ratio sellaslifesciences.com|SLS - Total Business Assets
- debt and liquidity data:
Total Debt to Capital SELLAS Life Sciences|SLS - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital SELLAS Life Sciences Group Inc.|SLS - Company Cumulative Debt|Debt to Book Capitalization Ratio SELLAS Life Sciences Group
Fundamental company valuation:SLS sellaslifesciences.com
Flagship merchandise of SELLAS Life Sciences Group, Inc.

Professional managers utilize fundamental filters to assess the actual volume of equity available per share of business after deducting all liabilities. This calculation logic, reflected in the book value per share, allows for an assessment of the intrinsic value of SELLAS Life Sciences (SLS), whose capitalization is supported by the retention of key immunologists through option programs and the advancement of its vaccine pipeline.

Competitor analysis

Net Assets per Single Share ONC (BeiGene Corp)|HALO - Net Assets per Share|RVMD (Revolution Medicines) - Book Value per Share|ascentage.com (AAPG) - Accounting Value per Share|CGON (CG Oncology) - Book Value per Share|Book Value per Share URGN|Net Assets per Single Share Bicara Bio BCAX|Equity per Share Personalis Genomics (PSNL)|Erasca, Inc. - Book Value per Share|Accounting Value per Share delcath.com DCTH|YMAB (Y-mAbs Therapeutics, Inc.) - Book Value per Share|AURA: Net Asset Value per Share|Net Assets per Single Share candeltx.com CADL|Accounting Value of a Share Accuray, Inc.|ACTU - Accounting Value per Share|Accounting Value of a Share citiusonc.com|Book Value per Share HURA (TuHURA Biosciences, Inc.)|Accounting Value per Share Protara Therapeutics Inc TARA|Accounting Value per Share FATE (Fate Therapeutics Corp)|Aadi Bioscience, Inc. - Book Value per Share|Net Assets per Single Share TScan (TCRX)|CSBR - Accounting Value of a Share|Book Value per Share XBIT|CVM (CEL-SCI) - Net Asset Value per Share|OSTX: Net Assets per Single Share|Net Assets per Share radiopharmtheranostics.com|Artiva Biotherapeutics, Inc. - Book Value per Share|Net Asset Value per Share ANL (adlainortye.com)|Net Assets per Single Share Veru VERU|Tempest Therapeutics Inc - Net Assets per Single Share|XLO - Net Assets per Single Share|RENB - Net Assets per Single Share|MURA: Book Value per Share|KAPA (Kairos Pharma) - Book Value per Share|OKUR: Net Assets per Single Share|Net Assets per Share CytoMed (GDTC)|Curis, Inc. (CRIS) - Accounting Value per Share|Accounting Value of a Share APLM (apollomicsinc.com)|Net Assets per Single Share Tharimmune, Inc. THAR|Net Assets per Single Share Advanced Biomed Inc. ADVB|Book Value per Share GNPX (Genprex)|CLDI - Net Assets per Share|Book Value per Share Sunshine Biopharma, Inc. (SBFM)|Xenetic Biosciences, Inc. (XBIO) - Share Book Value|Book Value per Share SLRX (Salarius Pharmaceuticals)|Net Asset Value per Share purple-biotech.com (PPBT)|American Oncology Network (AONC) - Accounting Value per Share|Accounting Value of a Share BGNE (BeiGene Ltd.)|Net Assets per Single Share CKPT|Net Assets per Share elevationoncology.com ELEV|ICAD: Book Value per Share|IKNA - Accounting Value per Share|Notable Labs - Book Value per Share|Viracta Therapeutics, Inc. (VIRX) - Net Assets per Share|Book Value per Share MOR (MorphoSys Corp)|Net Asset Value per Share NAYA|Net Assets per Single Share Ascentage Pharma Group AAPGV